Key Highlights
- Shares of Tempus AI skyrocketed nearly 24% following Merck and Moderna’s announcement of a successful Phase 3 trial for their cancer vaccine
- The positive trial data enhanced the strategic importance of Tempus AI’s pending $1.5 billion acquisition of Personalis, which supplies gene-sequencing technology for Moderna’s cancer initiative
- The company delivered its inaugural quarterly GAAP net profit of $5.6 million in Q2 2026, alongside 22% revenue growth reaching $382.5 million
- With over 26% of TEM’s float held short, a squeeze effect magnified upward price movement as bearish traders covered positions
- Wall Street analysts maintain a Moderate Buy rating on TEM shares with a consensus price target of $62.15
Shares of Tempus AI exploded nearly 24% higher on Wednesday, reaching approximately $59.64, following the announcement from Merck and Moderna of a significant Phase 3 breakthrough in their collaborative cancer vaccine initiative.
The timing couldn’t be better for Tempus AI. The company is currently finalizing its $1.5 billion acquisition of Personalis, a provider of gene-sequencing technology that forms a critical foundation for Moderna’s cancer vaccine development. The positive Phase 3 results instantly elevated the perceived value of this pending transaction.
TEM shares hit an intraday peak of $59.04 during morning trading before climbing even higher. The stock now trades substantially above its 52-week low of $40.77.
This dramatic move isn’t driven by a single catalyst. Multiple favorable developments have emerged for the company throughout recent weeks.
On July 30, Tempus AI reported its inaugural quarterly GAAP net profit of $5.6 million, a remarkable turnaround from the $42.8 million loss recorded in the comparable period last year.
Total revenue reached $382.5 million, representing 22% year-over-year expansion. Management subsequently increased its full-year 2026 revenue outlook to between $1.595 billion and $1.605 billion, while projecting Adjusted EBITDA near $65 million.
Heavy Short Interest Amplifies Gains
Over 26% of TEM’s available float is currently held in short positions. This elevated short interest transforms bullish catalysts into explosive moves. As shares rise, bearish traders scramble to close their positions by buying back stock, creating additional upward pressure.
On August 4, research published in Nature Medicine confirmed TEM’s PRISM2 AI platform as a highly accurate instrument for cancer detection and patient outcome prediction. This peer-reviewed validation provided independent scientific credibility to the company’s foundational technology.
Just two days later on August 6, Tempus AI unveiled a strategic collaboration with CellCarta, establishing Tempus as a commercial laboratory partner in CellCarta’s oncology companion diagnostics ecosystem.
Data licensing continues to accelerate as a revenue stream. The company disclosed a 36% year-over-year expansion in data licensing agreements with pharmaceutical companies including Merck and Gilead.
Wall Street’s Perspective
Broader market conditions remain supportive. The S&P 500 advanced 0.4% while the Nasdaq climbed 0.1% on Wednesday, though these moves pale in comparison to TEM’s explosive gains.
Wall Street analysts collectively rate TEM as a Moderate Buy, reflecting eight Buy recommendations and seven Hold ratings issued over the last three months. The consensus price target stands at $62.15.
Prior to Wednesday’s surge, TEM stock had already appreciated 8% over the previous three-month period.
The consensus analyst price target of $62.15 suggests approximately 4% additional upside from present trading levels.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
